{"id":"NCT04109976","sponsor":"UCB Biopharma SRL","briefTitle":"A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis","officialTitle":"A Multicenter, Randomized, Open-Label Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or Auto-Injector for the Subcutaneous Self-Injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-08-13","primaryCompletion":"2020-11-05","completion":"2020-11-13","firstPosted":"2019-10-01","resultsPosted":"2023-11-30","lastUpdate":"2023-11-30"},"enrollment":214,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Psoriatic Arthritis"],"interventions":[{"type":"DRUG","name":"Bimekizumab","otherNames":["UCB4940","BKZ"]}],"arms":[{"label":"Bimekizumab-SS","type":"EXPERIMENTAL"},{"label":"Bimekizumab-AI","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to evaluate for each self-injecting device presentation the ability of subjects with psoriatic arthritis (PsA) to safely and effectively self-inject bimekizumab at study start and 4 weeks after training in self-injection technique using the bimekizumab safety syringe (SS) or the bimekizumab auto-injector (AI).","primaryOutcome":{"measure":"Percentage of Participants Able to Self-administer Safe and Effective Injections Using the Bimekizumab Safety Syringe (BKZ-SS) or the Bimekizumab Auto-injector (BKZ-AI) at Week 4","timeFrame":"Week 4","effectByArm":[{"arm":"BKZ-SS-1mL 160 mg Q4W","deltaMin":100,"sd":null},{"arm":"BKZ-AI-1mL 160 mg Q4W","deltaMin":100,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":null},"locations":{"siteCount":47,"countries":["United States","Czechia","Germany","Hungary","Poland","Russia"]},"refs":{"pmids":[],"seeAlso":["https://www.ema.europa.eu/en/documents/product-information/bimzelx-epar-product-information_en.pdf","http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":107},"commonTop":[]}}